Loading
A phase 1/2 trial of DZD8586 in diffuse large b-cell lymphoma, run by Dizal Pharmaceuticals, now recruiting.
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) is a phase 1/2 interventional study registered as NCT07059650 by Dizal Pharmaceuticals, with 150 participants planned, started 2025-08-19 and due to reach its primary completion in 2030-10. Interventions recorded: DZD8586+R-CHOP, DZD8586+R-GemOx, DZD8586+BR. Conditions listed: Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.
Shares DZD8586, Dizal Pharmaceutical.
Shares DZD8586, Dizal Pharmaceutical.
Shares DZD8586, Dizal Pharmaceutical.